BALSALAZIDE (BioDeep_00000275561)

   


代谢物信息卡片


Balsalazida [Spanish];Balsalazide disodium;Balsalazido [Spanish];Balsalazidum [Latin]

化学式: C17H15N3O6 (357.096081)
中文名称: 巴柳氮
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O
InChI: InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)

描述信息

A - Alimentary tract and metabolism > A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents > A07E - Intestinal antiinflammatory agents > A07EC - Aminosalicylic acid and similar agents
D000893 - Anti-Inflammatory Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D012459 - Salicylates
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D002491 - Central Nervous System Agents > D000700 - Analgesics
D005765 - Gastrointestinal Agents
D018501 - Antirheumatic Agents

同义名列表

3 个代谢物同义名

BALSALAZIDE; Balsalazida [Spanish];Balsalazide disodium;Balsalazido [Spanish];Balsalazidum [Latin]; 5-[(E)-2-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazen-1-yl]-2-hydroxybenzoic acid



数据库引用编号

15 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • M H Sanad, Nermien M Gomaa, Nermeen M El Bakary, Ismail T Ibrahim, Ayman Massoud. Radioiodination of balsalazide, bioevaluation, and characterization as a highly selective radiotracer for imaging of ulcerative colitis in mice. Journal of labelled compounds & radiopharmaceuticals. 2022 03; 65(3):71-82. doi: 10.1002/jlcr.3961. [PMID: 34984721]
  • Eun-Ju Do, Sung Wook Hwang, Sang-Yeob Kim, Yeon-Mi Ryu, Eun A Cho, Eun-Ju Chung, Sunha Park, Hyo Jeong Lee, Jeong-Sik Byeon, Byong Duk Ye, Dong-Hoon Yang, Sang Hyoung Park, Suk-Kyun Yang, Jin-Ho Kim, Seung-Jae Myung. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. Journal of gastroenterology and hepatology. 2016 Aug; 31(8):1453-61. doi: 10.1111/jgh.13280. [PMID: 26711554]
  • U Klotz. Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2005 Jun; 37(6):381-8. doi: 10.1016/j.dld.2004.12.011. [PMID: 15893274]
  • W J Sandborn, S B Hanauer, A Buch. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Alimentary pharmacology & therapeutics. 2004 May; 19(10):1089-98. doi: 10.1111/j.1365-2036.2004.01964.x. [PMID: 15142198]
  • W J Sandborn, S B Hanauer. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Alimentary pharmacology & therapeutics. 2003 Jan; 17(1):29-42. doi: 10.1046/j.1365-2036.2003.01408.x. [PMID: 12492730]
  • Laurie M Edmond, Mark J Hopkins, Elizabeth A Magee, John H Cummings. The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria. Inflammatory bowel diseases. 2003 Jan; 9(1):10-7. doi: 10.1097/00054725-200301000-00002. [PMID: 12656132]
  • W Kruis, S Schreiber, D Theuer, J W Brandes, E Schütz, S Howaldt, B Krakamp, J Hämling, H Mönnikes, I Koop, M Stolte, D Pallant, U Ewald. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut. 2001 Dec; 49(6):783-9. doi: 10.1136/gut.49.6.783. [PMID: 11709512]
  • E Carceller, J Salas, M Merlos, M Giral, R Ferrando, I Escamilla, J Ramis, J García-Rafanell, J Forn. Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity. Journal of medicinal chemistry. 2001 Aug; 44(18):3001-13. doi: 10.1021/jm010852p. [PMID: 11520209]
  • I Kimura, M Kawasaki, A Matsuda, M Kataoka, Y Kokurba. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine. Arzneimittel-Forschung. 1998 Dec; 48(12):1163-7. doi: NULL. [PMID: 9893931]
  • T Kumamoto, A Matsuda, M Kataoka, Y Kokuba. Inhibition by aminosalicylates of lipid peroxidation in large intestinal mucosa after mesenteric ischemia/reperfusion in the rat. Japanese journal of pharmacology. 1997 Oct; 75(2):187-9. doi: 10.1254/jjp.75.187. [PMID: 9414034]
  • R P Chan, D J Pope, A P Gilbert, P J Sacra, J H Baron, J E Lennard-Jones. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Digestive diseases and sciences. 1983 Jul; 28(7):609-15. doi: 10.1007/bf01299921. [PMID: 6345112]
  • . . . . doi: . [PMID: 2864155]